KCM
KNSA icon

Kornitzer Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Kornitzer Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
20,672
-697
-3% -$36.2K 0.03% 381
2026
Q1 		$1.03M Sell
21,369
-722
-3% -$32K 0.02% 389
2025
Q4 		$911K Buy
+22,091
New +$886K 0.02% 420

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Kornitzer Capital Management's KNSA Position: Q2 2026 in Review

Kornitzer Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.3% in Q2 2026, selling an estimated $36.2K and leaving 20,672 shares worth $1.32M. The position accounts for 0.03% of the portfolio, ranked #381.

Kornitzer Capital Management first reported a position in KNSA in Q4 2025 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Kornitzer Capital Management held 20,672 shares of Kiniksa Pharmaceuticals worth $1.32M as of Q2 2026.
  • Kornitzer Capital Management sold 697 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $36.2K.
  • Kiniksa Pharmaceuticals made up 0.03% of Kornitzer Capital Management's portfolio in Q2 2026, its #381 holding.
  • Kornitzer Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.